Rosen Law Firm alerts Capricor Therapeutics investors of September 2 lead plaintiff deadline in securities fraud class action
Executive summary: Rosen Law Firm reminded purchasers of Capricor Therapeutics securities between Dec 17, 2025 and July 26, 2026 about the September 2, 2026 lead plaintiff deadline in a securities fraud class action. Failing to meet the deadline prevents investors from serving as lead plaintiff, limiting their influence over the lawsuit and potential recovery.
Who is involved: Rosen Law Firm, Capricor Therapeutics investors, putative class members, and the overseeing court.
Likely next: Investors may submit lead plaintiff applications before September 2; if none are filed, the court will appoint a lead plaintiff.
Rosen Law Firm issued a reminder on August 24, 2026 that investors who bought Capricor Therapeutics (NASDAQ: CAPR) shares between December 17, 2025 and July 26, 2026 have until September 2, 2026 to seek appointment as lead plaintiff in a pending securities fraud class action. The notice repeats earlier alerts from other law firms and highlights the approaching deadline for lead plaintiff applications. Missing the deadline would bar those investors from leading the litigation, though they could still participate as class members.
Timeline
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- September 2, 2026: lead plaintiff deadline for Capricor Therapeutics securities fraud class action
- August 28, 2026: lead plaintiff deadline for Genius Group securities fraud class action
- October 5, 2026: lead plaintiff deadline for ARS Pharmaceuticals securities fraud class action
- August 24, 2026: Rosen Law Firm reminder for Aardvark Therapeutics securities fraud class action (no specific deadline given)
Sectors affected
- biotechnology
Regulatory implications
- SEC may pursue enforcement under Securities Exchange Act of 1934 §10(b) and Rule 10b-5 if fraud is proven
Key entities
Sources
- CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit — PR Newswire
Related cases
- Capricor Therapeutics faces a looming lead plaintiff deadline that could shape the outcome of its securities class action lawsuit
- Capricor Therapeutics faces a class‑action securities lawsuit alleging violations of exchange‑act provisions, triggering potential legal costs and investor scrutiny
- SBS Law invites investors to lead a securities‑fraud class action against Capricor Therapeutics, highlighting a broader pattern of similar shareholder‑rights actions
- ClaimsFiler alerts Capricor Therapeutics investors with over $100k losses to file lead plaintiff applications by September 28, 2026
- Capricor Therapeutics faces a class-action securities lawsuit alleging violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934
- SBS highlights investor chance to lead securities fraud class action against Capricor Therapeutics, underscoring rising litigation risk in the biotech sector